Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proellex in Symptomatic Uterine Fibroids
NCT00683917Phase 2Terminated
- Sponsor
- Repros Therapeutics Inc.
- Start
- May 2008
- Primary completion
- Aug 2009
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, randomised trial of telapristone in Uterine Fibroids (UF) (3 arms), sponsored by Repros Therapeutics Inc. Primary endpoint: Pharmacokinetic Characteristics at 4 months. Started May 2008; status: terminated.
02
Drugs
telapristone
03
Conditions
Uterine Fibroids (UF)
Beyond the preview
Go deeper on NCT00683917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00683917.